|Bid||365.15 x 800|
|Ask||367.39 x 1000|
|Day's range||363.33 - 369.73|
|52-week range||260.73 - 401.78|
|Beta (5Y monthly)||0.61|
|PE ratio (TTM)||16.84|
|Earnings date||03 May 2023 - 08 May 2023|
|Forward dividend & yield||2.16 (0.59%)|
|Ex-dividend date||28 Feb 2023|
|1y target est||421.31|
Delays in recruitment for some large research projects in the Americas and Europe, the impact of COVID disruptions in China and foreign exchange woes hurt Illumina's (ILMN) Q4 revenues.
The ongoing double-digit sales growth in the non-COVID product portfolio contributed to QIAGEN's (QGEN) Q4 revenues.
CVS Health's (CVS) Retail/LTC segment revenues rise on increased prescription and front store volume, pharmacy drug mix and brand inflation.